Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  JIM - Journal of Immunological Methods

• Publication date

  2002-09-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0022-1759(02)00148-5PMID 12165442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and application of diabodies, triabodies and tetrabodies for cancer targeting.

  2001cited by this paper
• Bispecific human IgG by design.

  2001cited by this paper
• Introduction: bispecific antibodies.

  2001cited by this paper
• Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.

  2001cited by this paper
• Immunotherapeutic perspective for bispecific antibodies.

  2000cited by this paper
• Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies*

  2000cited by this paper
• Immunotherapeutic perspective for bispecific antibodies.

  2000cited by this paper
• Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.

  2000cited by this paper
• An efficient route to the production of an IgG-like bispecific antibody.

  2000cited by this paper
• Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1

  2000cited by this paper
• Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

  1999cited by this paper
• Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

  1998cited by this paper
• The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

  1998cited by this paper
• Bispecific antibodies as novel bioconjugates.

  1998cited by this paper
• An efficient route to human bispecific IgG

  1998cited by this paper
• Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

  1997cited by this paper
• Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris.

  1997cited by this paper
• Design and production of novel tetravalent bispecific antibodies

  1997cited by this paper
• New protein engineering approaches to multivalent and bispecific antibody fragments.

  1997cited by this paper
• Remodeling domain interfaces to enhance heterodimer formation

  1997cited by this paper
• Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library (*)

  1996cited by this paper
• High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions

  1996cited by this paper
• 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

  1996cited by this paper
• High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli

  1996cited by this paper
• Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells

  1995cited by this paper
• Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.

  1995cited by this paper
• A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

  1995cited by this paper
• Toward the Production of Bispecific Antibody Fragments for Clinical Applications

  1995influential reference
• Construction, expression, and activity of a bivalent bispecific single-chain antibody.

  1994cited by this paper
• Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia coli

  1993cited by this paper
• "Diabodies": small bivalent and bispecific antibody fragments.

  1993cited by this paper
• Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

  1992cited by this paper
• Formation of a bispecific antibody by the use of leucine zippers.

  1992cited by this paper
• Bispecific monoclonal antibodies from hybrid hybridomas.

  1986cited by this paper
• [17] Bispecific monoclonal antibodies from hybrid hybridomas

  1986cited by this paper

• Strategies for the Generation of Bispecific Antibodies

  2025cites this paper
• Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment

  2025cites this paper
• [Advances of monoclonal antibodies and analysis of marketed antibody drugs].

  2024cites this paper
• Characterization of a novel format scFv×VHH single‐chain biparatopic antibody against metal binding protein MtsA

  2024cites this paper
• Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

  2023cites this paper
• TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

  2023cites this paper
• A T cell redirection platform for co-targeting dual antigens on solid tumors

  2021cites this paper
• LegoBody: facile generation of bispecific and multi-specific antibodies

  2019cites this paper
• Multivalent Antibody-Nanoparticle Conjugates To Enhance the Sensitivity of Surface-Enhanced Raman Scattering-Based Immunoassays.

  2018cites this paper
• Anticorps bispécifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr

  2018cites this paper
• Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule.

  2017cites this paper
• Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.

  2017cites this paper
• DAGNOSIS AND EVALUATION OF CANCER

  2017cites this paper
• The making of bispecific antibodies

  2017cites this paper
• An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants.

  2016cites this paper
• Quantification of cell surface proteins with bispecific antibodies

  2013cites this paper
• Fc-Based Cytokines

  2012cites this paper
• Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

  2011cites this paper
• Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases.

  2011cites this paper
• Bispecific Antibodies and Immune Therapy Targeting

  2011cites this paper
• Bispecific Antibodies: Developments and Current Perspectives

  2011cites this paper
• Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris

  2009cites this paper
• Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy

  2008cites this paper
• Protéines de liaison à épitope multispécifiques et leurs utilisations

  2008cites this paper
• Fc-based cytokines : prospects for engineering superior therapeutics.

  2008cites this paper
• Vascular endothelial growth factor (VEGF) inhibition--a critical review.

  2007cites this paper
• Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.

  2007cites this paper
• Periplasmic Expression of Antibody Fragments

  2007cites this paper
• Eukaryotic expression vectors and immunoconjugates for cancer therapy

  2006cites this paper
• Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.

  2006cites this paper
• A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.

  2006cites this paper
• Single Variable Domain-IgG Fusion

  2006cites this paper
• Recombinant approaches to IgG-like bispecific antibodies

  2005cites this paper
• Survey of the year 2003 commercial optical biosensor literature

  2005cites this paper
• Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

  2004cites this paper
• Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody*

  2004cites this paper
• Generation, Engineering and Production of Human Antibodies Using Hucal®

  2004cites this paper
• Antibody Fragments: Production, purification and formatting for therapeutic applications

  2004cites this paper
• New Strategies in Polypeptide and Antibody Synthesis: An Overview

  2004cites this paper
• Anticorps a double specificite de substitution de proteine fonctionnelle

  2003cites this paper
• Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification.

  2003cites this paper
• Designing proteins for therapeutic applications.

  2003cites this paper
• A survey of the year 2002 commercial optical biosensor literature

  2003cites this paper
• Recombinant antibodies for cancer diagnosis and therapy

  2003cites this paper
• Di-diabody: a novel tetravalent bispecific antibody molecule by design.

  2003cites this paper
• Anticorps agoniste dirigé contre un hétérorécepteur

  2003cites this paper
• Recombinant antibodies for cancer diagnosis and therapy

  2001cites this paper